Back to School: How biopharma can reboot drug development. Access exclusive analysis here

APD403: Phase II data

A double-blind, Danish Phase II trial in 342 cancer patients receiving highly emetogenic chemotherapy (HEC) showed that APD403

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE